(Q37291434)

19 August 2017

1 reference

title

New technologies in cervical cancer screening (English)

1 reference

19 August 2017

main subject

cervix uterine cancer

1 reference

6

Cosette M Wheeler

1 reference

19 August 2017

2

François Coutlée

1 reference

19 August 2017

Patti E Gravitt

1

1 reference

19 August 2017

Thomas Iftner

series ordinal

3

1 reference

19 August 2017

John W Sellors

series ordinal

4

1 reference

19 August 2017

Wim G V Quint

series ordinal

5

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26 Suppl 10

1 reference

19 August 2017

page(s)

K42-52

1 reference

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Clinical utility of HPV genotyping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

2006 consensus guidelines for the management of women with abnormal cervical screening tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Outcomes After Treatment of Cervical Intraepithelial Neoplasia Among Women With HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Detection and Typing of Multiple Genital Human Papillomaviruses by DNA Amplification with Consensus Primers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Recovery of human papillomavirus nucleic acids from liquid-based cytology media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Effects of fixation on RNA integrity in a liquid-based cervical cytology setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Chapter 12: Human papillomavirus technologies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Type-dependent integration frequency of human papillomavirus genomes in cervical lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

p16 expression in the female genital tract and its value in diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

The natural history of cervical HPV infection: unresolved issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Clonal selection for transcriptionally active viral oncogenes during progression to cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Detection of Genomic Amplification of the Human Telomerase Gene (TERC) in Cytologic Specimens as a Genetic Test for the Diagnosis of Cervical Dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Improved cervical smear assessment using antibodies against proteins that regulate DNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Cost-effectiveness of cervical-cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Self-collected samples for testing of oncogenic human papillomavirus: a systematic review

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

inferred from DOI database lookup

7 January 2021

based on heuristic

The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Chapter 19: Cost-effectiveness of cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.002

10.1016/J.VACCINE.2008.05.002

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference